Advertisement

European Journal of Clinical Pharmacology

, Volume 42, Issue 2, pp 171–174 | Cite as

Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans

  • L. A. Salako
  • A. Sowunmi
Originals

Summary

The pharmacokinetics of quinine has been studied in ten healthy adult Africans after intravenous infusion and oral ingestion of a 500 mg dose. Blood and saliva samples were collected over 48 h and quinine in plasma, red cells and saliva was determined by HPLC.

Quinine was rapidly and almost completely absorbed after an oral dose, with absorption half-life of 0.53 h, a tmax of 1–3 h and a bioavailability of 88%. Analysis of the i. v. data gave an apparent volume of distribution of 3.6 1·kg−1 and a plasma clearance of 0.19 l·kg−1·h−1. The concentration-time curves for plasma, red cells and saliva had declining phases were approximately parallel, giving a similar half-life that in all three media. The half-lives after the i. v. infusion also did not different from those after oral administration. The dose was well tolerated by both methods of administration.

Key words

Quinine Malaria pharmacokinetics red blood cells plasma saliva adverse effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berlin CM, Stackman JM, Vessel ES (1975) Quinine-induced alteration in drug disposition. Clin Pharmacol Ther 18: 670–679Google Scholar
  2. Ekanem OJ (1985) Plasmodium falciparum falciparum malaria not responding to chloroquine in Nigeria. Trans Roy Soc Trop Med Hyg 79: 141Google Scholar
  3. Jamaludin A, Mohamad M, Navaratnam V, Selliah K, Tan SC, Wernsdorfer WH, Yuen KH (1988) Relative bioavailability of the hydrochloride, sulphate and ethyl carbonate salts of quinine. Br J Clin Pharmacol 25: 261–263Google Scholar
  4. Mansor SM, Taylor TE, McGrath CS, Edwards G, Ward SA, Wirima JJ, Molyneux ME (1990) The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Trans Roy Soc Trop Med Hyg 84: 482–487Google Scholar
  5. Matin SB, Wan SH, Karam JH (1974) Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther 16: 1052–1058Google Scholar
  6. Mihaly GW, Ching MS, Klejn MB, Paull J, Smallwood RA (1987) Differences in protein binding of quinine and quinidine to plasma proteins. Br J Clin Pharmacol 24: 769–774Google Scholar
  7. Salako LA, Aderounmu AF (1987) In-vitro chloroquine and mefloquine resistant Plasmodium falciparum in Nigeria. Lancet 2: 572–573Google Scholar
  8. Salako LA (1987) Quinine and malaria: The African experience. Acta Leidensia 55: 167–180Google Scholar
  9. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T (1982) Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med 73: 564–572Google Scholar
  10. White NJ, Chanthavanich P, Krishna S, Bunch C, Silamut K (1983) Quinine disposition kinetics. Br J Clin Pharmacol 16: 399–404Google Scholar
  11. White NJ (1985) Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10: 181–215Google Scholar
  12. WHO Malaria Action Programme (1986) Severe and Complicated Malaria. Trans Roy Soc Trop Med Hyg 80 [Suppl]: 1–50Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • L. A. Salako
    • 1
  • A. Sowunmi
    • 1
  1. 1.Department of Pharmacology and TherapeuticsUniversity of IbadanIbadanNigeria

Personalised recommendations